Apr 21, 2015
Lytix Biopharma at AACR with poster
Andrew Saunders (CMO) and Øystein Rekdal (CSO) are representing Lytix Biopharma at the American Association for Cancer Research (AACR) in Philadelphia April 18-23, 2015. Leading scientists and a large number of pharmaceutical companies are attending, and the mission is to prevent and cure cancer through research, education, communication and collaboration.
Lytix Biopharma is presenting a poster at AACR showing strong synergy with LTX-315 and cyclophosphamide in an experimental lymphoma model. The poster entitled “Anticancer effects obtained against A20 lymphomas following treatment with LTX-315 (Oncopore™) in combination with low-dose cyclophosphamide” was presented on April 21, from 1.00PM to 5.00PM in Poster Section 24, Poster number 13.
Øystein Rekdal (CSO) and Ketil Camilio
Lytix Biopharma is presenting a poster at AACR showing strong synergy with LTX-315 and cyclophosphamide in an experimental lymphoma model. The poster entitled “Anticancer effects obtained against A20 lymphomas following treatment with LTX-315 (Oncopore™) in combination with low-dose cyclophosphamide” was presented on April 21, from 1.00PM to 5.00PM in Poster Section 24, Poster number 13.
Øystein Rekdal (CSO) and Ketil Camilio